Clinical bottom line
Pediatric sudden-onset sensorineural hearing loss (SSNHL) with suspected viral etiology remains a diagnostic and therapeutic challenge. Emerging evidence suggests viral labyrinthitis and other viral insults may underlie a subset of cases, but definitive diagnostic biomarkers are lacking. Current management relies primarily on prompt corticosteroid therapy, with adjunctive antiviral treatment considered on a case-by-case basis. Advanced imaging such as MRI can help exclude alternative diagnoses but does not reliably confirm viral involvement. Clinicians should maintain a high index of suspicion for viral causes in children presenting with acute unilateral hearing loss, especially when accompanied by vertigo, and tailor treatment accordingly while awaiting further validation of targeted antiviral strategies.
What the evidence shows
Sudden sensorineural hearing loss in children is rare but clinically significant, with viral infections implicated as a common putative cause (Hanson et al., 2026). Viral labyrinthitis, often caused by herpesviruses or enteroviruses, can present with acute unilateral hearing loss and vertigo, mimicking idiopathic SSNHL (Spitz et al., 2026). Distinguishing viral labyrinthitis from idiopathic SSNHL is challenging due to overlapping clinical features and the absence of specific laboratory or imaging markers (Herrera et al., 2024).
MRI is routinely employed to exclude retrocochlear pathology and inner ear malformations but has limited sensitivity for detecting viral inflammation (Herrera et al., 2024). Diagnostic workup may include viral serologies or PCR from cerebrospinal fluid in select cases, though these are not standardized or widely validated in pediatric SSNHL (Rodríguez Izquierdo et al., 2024).
Therapeutically, systemic corticosteroids remain the mainstay, with evidence supporting improved hearing recovery when initiated promptly (Hanson et al., 2026). The role of antiviral agents is less clear; some clinicians advocate their use in suspected viral cases, but robust clinical trial data are lacking (Luu et al., 2023). Supportive care and vestibular rehabilitation may benefit patients with vertigo symptoms (Spitz et al., 2026).
Practice patterns vary widely, reflecting ongoing uncertainty about etiology and optimal management (Luu et al., 2023). Small case series suggest that early intervention may improve outcomes, but heterogeneity in study design and small sample sizes limit definitive conclusions (Dedhia et al., 2016).
Caveats and uncertainty
The evidence base for viral etiologies in pediatric SSNHL is limited by small cohorts, retrospective designs, and lack of standardized diagnostic criteria (Herrera et al., 2024; Luu et al., 2023). Viral identification is often presumptive, based on clinical presentation rather than direct pathogen detection. MRI findings are nonspecific and cannot reliably differentiate viral labyrinthitis from other causes (Herrera et al., 2024).
There is no consensus on the routine use of antivirals, and their efficacy remains unproven in controlled trials. Corticosteroid dosing, timing, and duration vary widely across studies and clinical practice, complicating interpretation of outcomes (Hanson et al., 2026). Additionally, pediatric patients may have different pharmacodynamics and recovery trajectories compared to adults.
Long-term hearing outcomes and the risk of recurrence or progression are incompletely characterized, underscoring the need for prospective, multicenter studies. The heterogeneity of viral pathogens and host immune responses further complicates the development of targeted therapies.
How this may change practice
Clinicians should consider viral etiologies in pediatric patients presenting with sudden unilateral sensorineural hearing loss, particularly when vertigo is present. Prompt initiation of corticosteroid therapy remains standard, with careful monitoring for hearing improvement. MRI should be used to exclude alternative diagnoses but not relied upon to confirm viral involvement.
Pending further evidence, antiviral therapy may be considered in select cases with strong clinical suspicion, ideally within clinical trial settings or multidisciplinary consultation. Enhanced diagnostic protocols incorporating viral PCR or serologies may emerge as research advances.
This evolving understanding encourages otolaryngologists to adopt a nuanced, individualized approach, balancing early aggressive treatment with judicious use of adjunctive therapies. Future developments in molecular diagnostics and antiviral agents hold promise to refine management and improve outcomes in this challenging population.